Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with insulin resistance (IR), metabolic syndrome and increased cardiovascular risk. Adipokines are biologically active, pleotropic molecules which have been involved in the development of IR and in the pathogenesis of several chronic inflammatory conditions. The aim of the present study was to analyze serum concentrations of adiponectin, leptin, resistin and visfatin in patients with HS, and investigate their possible associations with IR, HS risk and disease severity. This case–control study enrolled 137 non-diabetic individuals (76 HS-patients and 61 age and sex-matched controls). Serum concentrations of adiponectin, leptin, resistin and visfatin, and the homeostasis model assessment of IR (HOMA-IR) were measured in all the participants. Serum adiponectin concentrations were found to be significantly lower, and leptin, resistin and visfatin levels were significantly higher in HS-patients than in controls. These differences remained significant even after adjusting for age, sex and body mass index, except for leptin. In a multivariate regression analysis, HOMA-IR was inversely correlated with adiponectin and positively associated with resistin levels. Furthermore, serum levels of resistin and visfatin were independently associated with HS risk. However, we found no association between serum levels of adipokines and HS severity. Our results suggest that reduced adiponectin and increased resistin serum levels may be surrogate biomarkers for IR in patients with HS. Moreover, resistin and visfatin might be independent risk factors for the development of HS.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Negus D, Ahn C, Huang W (2018) An update on the pathogenesis of hidradenitis suppurativa: implications for therapy. Expert Rev Clin Immunol 14(4):275–283

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Vossen ARJV, van der Zee HH, Prens EP (2018) Hidradenitis Suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol 14(9):2965

    Article  Google Scholar 

  4. 4.

    Fimmel S, Zouboulis CC (2010) Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2(1):9–16

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J (2018) Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 32(1):129–144

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Pescitelli L, Ricceri F, Prignano F (2018) Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 153(3 Suppl 2):8–17

    PubMed  Google Scholar 

  7. 7.

    Vilanova I, Hernández JL, Mata C, Durán C, García-Unzueta MT, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R, González-López MA (2018) Insulin resistance in hidradenitis suppurativa: a case–control study. J Eur Acad Dermatol Venereol 32(5):820–824

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Phan K, Charlton O, Smith SD (2019) Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clin Exp Dermatol 44(4):e126–e132

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Phan K, Charlton O, Smith SD (2019) Hidradenitis suppurativa and metabolic syndrome-systematic review and adjusted meta-analysis. Int J Dermatol. https://doi.org/10.1111/ijd.14500

    PubMed  Article  Google Scholar 

  10. 10.

    González-López MA, Hernández JL, Lacalle M, Mata C, López-Escobar M, López-Mejías R, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R (2016) Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa. J Am Acad Dermatol 75(2):329–335

    PubMed  Article  Google Scholar 

  11. 11.

    Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434

    PubMed  Article  Google Scholar 

  12. 12.

    Gremese E, Tolusso B, Gigante MR, Ferraccioli G (2014) Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 11(5):576

    Google Scholar 

  13. 13.

    Żelechowska P, Kozłowska E, Pastwińska J, Agier J, Brzezińska-Błaszczyk E (2018) Adipocytokine involvement in innate immune mechanisms. J Interferon Cytokine Res. https://doi.org/10.1089/jir.2018.0102

    PubMed  Article  Google Scholar 

  14. 14.

    Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115(5):911–919

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Francisco V, Ruiz-Fernández C, Pino J, Mera A, González-Gay MA, Gómez R, Lago F, Mobasheri A, Gualillo O (2019) Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol 165:196–206

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2017) Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 233(5):378–389

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H (2017) Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 9(1):1266–1278

    PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19(7):672–677

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Malara A, Hughes R, Jennings L, Sweeney CM, Lynch M, Awdeh F, Timoney I, Tobin AM, Lynam-Loane K, Tobin L, Hogan A, O'Shea D, Kirby B (2018) Adipokines are dysregulated in patients with hidradenitis suppurativa. Br J Dermatol 178(3):792–793

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Akdogan N, Alli N, Uysal PI, Topcuoglu C, Candar T, Turhan T (2018) Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study. Arch Dermatol Res 310(10):785–793

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report (2002). Circulation 106:3143–3421

    Article  Google Scholar 

  22. 22.

    López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S (2014) The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 18(1):37–45

    PubMed  Google Scholar 

  23. 23.

    Uslu S, Kebapçi N, Kara M, Bal C (2012) Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med 4(1):113–120

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gómez-Reino JJ, Mera A, Lago F, Gómez R, Gualillo O (2017) Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol 13(2):100–109

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J (2009) Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27(2):222–228

    CAS  PubMed  Google Scholar 

  26. 26.

    Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA (2015) Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J Eur Acad Dermatol Venereol 29(10):1995–2001

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA (2014) Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int 2014:860651

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Bannigida DM, Nayak SB (2018) Serum visfatin and adiponectin—markers in women with polycystic ovarian syndrome. Arch Physiol Biochem 13:1–4

    Article  Google Scholar 

Download references

Funding

This study was funded through an unrestricted Grant provided by AbbVie.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Marcos A. González-López.

Ethics declarations

Conflict of interest

Dr. Marcos A. González López had consultation fees/participation in company sponsored speaker’s bureau from Abbvie. Dr. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker ́s bureau from Pfizer, Lilly, Roche and Sanofi. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker ́s bureau from Abbvie, Pfizer, Roche, Bristol Myers, Janssen and MSD. The rest of the authors have no conflict of interest to declare regarding this paper.

Ethical protocol

The research protocol was approved by the Ethics Committee of Cantabria (Spain). All study procedures were performed in accordance with the ethical principles of the 1964 Declaration of Helsinki and written informed consent was obtained from all the subjects.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

González-López, M.A., Vilanova, I., Ocejo-Viñals, G. et al. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Arch Dermatol Res 312, 595–600 (2020). https://doi.org/10.1007/s00403-019-02018-4

Download citation

Keywords

  • Hidradenitis suppurativa
  • Adiponectin
  • Leptin
  • Resistin
  • Visfatin
  • Insulin resistance